Universitair Ziekenhuis Brussel

Running trials

• Not yet recruiting

  A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

  NCT07789015· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Assessment of self-perceived stress and repetitive behaviors after six weeks of daily intranasal oxytocin administration versus placebo: a randomised, multicentre, parallel group pragmatic trial in 210 men and women with autism

  2025-524797-42-00· Phase 3· UZ Leuven· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

  NCT07781657· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  2024-518365-10-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Recruiting

  A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN

  NCT07773727· Phase 2· argenx· Source

• Recruiting

  ENDO-REAL: Endometriosis and Reproductive Enhancement with Letrozole

  2025-524995-53-00· Phase 4· UZ Brussel· Source

• Recruiting

  Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

  NCT07817875· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Incyte Corp.· Source

• Recruiting

  Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

  NCT07770841· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  Phase II study of ezabenlimab in patients with PD-L1-positive head and neck cancer with residual disease detected by ctDNA after chemoradiotherapy

  2025-523575-36-00· Phase 2· Cliniques Universitaires Saint-Luc· Source

• Recruiting

  A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

  NCT07492680· Phase 2· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  The Value of Spleen Stiffness Measurement in Patients With PBC

  NCT07319169· Universitair Ziekenhuis Brussel· Source

• Recruiting

  A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer

  2025-522818-23-00· Phase 3· Zai Lab (US) LLC· Source

• Recruiting

  OPTION-EMEA Clinical Trial

  NCT07349121· Boston Scientific Corporation· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

  NCT07525206· Phase 3· AbbVie· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)

  NCT07545759· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)

  NCT07545772· Phase 2· Eli Lilly and Company· Source

• Recruiting

  An investigational trial to evaluate the effects of the drug XC001 delivered via a catheter in subjects with chronic angina caused by coronary artery disease (EXACT-2 Trial)

  2024-514874-36-01· Phase 2· Xylocor Therapeutics Inc.· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  Exploring the Modulatory Effect of the Dialyzer Membrane Choice on Hemodialysisassociated Thromboinflammation: a Prospective Randomized Cross-over Trial

  NCT07682701· Universitair Ziekenhuis Brussel· Source

• Recruiting

  Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)

  NCT07298473· Medtronic Cardiac Ablation Solutions· Source

• Recruiting

  Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration

  NCT07523620· Abbott Medical Devices· Source

• Recruiting

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07491445· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Incyte Corporation· Source

• Recruiting

  A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

  NCT07222332· Phase 3· Eli Lilly and Company· Source

• Recruiting

  LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer

  NCT06831955· Phase 2· Universitaire Ziekenhuizen KU Leuven· Source

• Recruiting

  Preventive Effect of a Dietary Supplement With Two Probiotic Limosilactobacillus Reuteri Strains on Excessive Crying and Colic in Healthy Newborns.

  NCT07347743· Universitair Ziekenhuis Brussel· Source

• Recruiting

  A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

  NCT07222137· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

  NCT07253285· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT07222761· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  NCT07063745· Phase 2/3· Bristol-Myers Squibb· Source

• Not yet recruiting

  Comparison of two treatments (intrathecal baclofen pump and selective dorsal rhizotomy) for children with cerebral palsy who cannot walk

  2024-518822-33-01· Phase 4· UZ Leuven· Source

• Not yet recruiting

  Pre- and post-treatment evaluation of lung function with Xenon-gas enhanced Dual-Energy CT-imaging in patients undergoing radiotherapy

  2025-521559-22-00· Phase 2/3· UZ Brussel· Source

• Active, not recruiting

  BaLloon-based PFA Ablation poST Approval Outcomes for PAF and PersAF

  NCT07181590· Abbott Medical Devices· Source

• Recruiting

  Assessment of Pulmonary Vein Isolation Using a Balloon Catheter With Pulsed Field Energy in Atrial Fibrillation

  NCT07156877· Sebastien Knecht· Source

• Recruiting

  A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

  NCT07230691· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

  NCT07218146· Phase 3· Zai Lab (Shanghai) Co., Ltd.· Source

• Recruiting

  SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

  NCT07187531· Phase 2· SAb Biotherapeutics, Inc.· Source

• Active, not recruiting

  OCT-A Biomarkers for Cognitive Impairment in Patients With Chronic Atrial Fibrillation

  NCT07607756· Universitair Ziekenhuis Brussel· Source

• Recruiting

  Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  NCT07085767· Phase 3· Olema Pharmaceuticals, Inc.· Source

• Recruiting

  ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  NCT07173751· Phase 3· BioNTech SE· Source

• Recruiting

  Increasing the dosing interval of osimertinib in patients with EGFR mutated locally advanced or meta-static non-small cell lung cancer - OSI-SAVE

  2024-514693-47-01· Phase 4· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Active, not recruiting

  AI for Detection of Brain Aneurysm: Low-cost Opportunistic Screening

  NCT07123818· Ziekenhuis Oost-Limburg· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

  2024-516654-22-00· Phase 3· Amgen Inc.· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Janssen Research & Development, LLC· Source

Showing 50 of 213.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer18 recruiting
• Crohn's disease9 recruiting
• Melanoma8 recruiting
• Atrial fibrillation7 recruiting
• Coronary artery disease6 recruiting
• Irritable bowel syndrome6 recruiting
• Stroke6 recruiting
• Ulcerative colitis6 recruiting
• Colorectal cancer5 recruiting
• Metastatic breast cancer5 recruiting
• Obesity5 recruiting
• Pancreatic cancer5 recruiting
• Triple-negative breast cancer5 recruiting
• Acute myeloid leukaemia4 recruiting
• Multiple myeloma4 recruiting
• Type 1 diabetes4 recruiting
• Childhood cancers3 recruiting
• Chronic kidney disease3 recruiting
• COPD3 recruiting
• Fatty liver disease (MASLD/MASH)3 recruiting
• Liver and biliary tract cancer3 recruiting
• Prostate cancer3 recruiting
• Amyloidosis2 recruiting
• Atopic dermatitis (eczema)2 recruiting
• Depression2 recruiting
• Glioblastoma2 recruiting
• Head and neck cancer2 recruiting
• Hearing loss2 recruiting
• Heart failure2 recruiting
• Liver cirrhosis2 recruiting
• Multiple sclerosis2 recruiting
• Psoriasis2 recruiting
• Type 2 diabetes2 recruiting
• Alzheimer disease1 recruiting
• Asthma1 recruiting
• Autism1 recruiting
• Bladder cancer1 recruiting
• Cerebral palsy1 recruiting
• Cervical cancer1 recruiting
• Cystic fibrosis1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Endometrial cancer1 recruiting
• Endometriosis1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• High blood pressure1 recruiting
• HIV1 recruiting
• Hypothyroidism1 recruiting
• IgA nephropathy1 recruiting
• Myelodysplastic syndromes1 recruiting
• Obstructive sleep apnoea1 recruiting
• Ovarian cancer1 recruiting
• Primary biliary cholangitis1 recruiting
• Psoriatic arthritis1 recruiting
• Rheumatoid arthritis1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Closed trials

• Completed

  Effect of Blink-Based Training on Cancer Detection in Colorectal Polyp Images by Medical Students/Non GI-trainees

  NCT07401004· Universitair Ziekenhuis Brussel· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Recruiting

  Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function

  NCT06943469· Société des Produits Nestlé (SPN)· Source

• Completed

  Feasibility of an Augmented Two-Day Step Test and Causal Modeling for Post-Exertional Symptom Exacerbation in Post Covid-19 Syndrome

  NCT06933017· Universitair Ziekenhuis Brussel· Source

• Completed

  A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia

  2024-511057-22-00· Phase 3· Janssen Cilag International· Source

• Withdrawn

  3rd Generation Resorbable Magnesium Scaffolds vs Biodegradable Polymer Stents in NSTE/ACS

  NCT06409117· Konstantinos Toutouzas· Source

• Recruiting

  A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

  NCT06585787· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Completed

  FOCALFLEX (CE Mark) Study

  NCT06271967· Abbott Medical Devices· Source

• Completed

  A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

  NCT06522997· Phase 2· Bayer· Source

• Active, not recruiting

  A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

  NCT06544616· Phase 2· Janssen Pharmaceutica N.V., Belgium· Source

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067· Phase 3· Erasca, Inc.· Source

• Completed

  A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)

  NCT05865886· Phase 2· Boehringer Ingelheim· Source

• Completed

  VOLT-AF IDE Clinical Study

  NCT06223789· Abbott Medical Devices· Source

• Completed

  Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

  NCT06241313· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06260163· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Pharmacokinetics of inhaled levosimendan: a pilot study

  2024-514318-11-00· Phase 1· UZ Brussel· Source

• Recruiting

  BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

  NCT06059638· Orchestra BioMed, Inc· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

  NCT06066528· Phase 3· Boehringer Ingelheim· Source

• Completed

  A 14-week Pilot Prospective Clinical Trial With BiOkuris Product in Patients With Irritable Bowel Syndrome

  NCT05780749· Biokuris s.a.· Source

• Completed

  Mavacamten Impact on Myocardial Structure in Obstructive Hypertrophic Cardiomyopathy

  2022-502316-36-00· Phase 4· Myokardia Inc.· Source

• Completed

  A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage

  NCT05970224· Phase 2· Bioxodes S.A.· Source

• Completed

  Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant

  NCT05978622· AbbVie· Source

• Completed

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· Phase 3· Amgen Inc.· Source

• Active, not recruiting

  A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

  NCT06045806· Phase 3· Celgene· Source

• Terminated

  A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

  NCT05983367· Phase 2· Inspirna, Inc.· Source

• Completed

  The Effect of GLP-1 Analogues on Liver Steatosis and Fibrosis in Diabetic and Obese Patients in a Clinical Setting

  NCT07021443· Universitair Ziekenhuis Brussel· Source

• Completed

  Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine

  NCT05748483· Phase 3· AbbVie· Source

• Completed

  A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC OLE)

  NCT05604170· Phase 3· Marinus Pharmaceuticals Inc.· Source

• Completed

  Pulsed ElectRic FiEld Versus Cryoballoon for PAF

  NCT07100834· Universitair Ziekenhuis Brussel· Source

• Completed

  Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

  NCT05882734· Phase 1/2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  A study to investigate response to ompenaclid combined with FOLFIRI plus bevacizumab in patients with advanced or metastatic colorectal cancer

  2023-503356-27-00· Phase 2· Inspirna Inc.· Source

• Completed

  A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

  NCT05953480· Phase 2· Shionogi· Source

• Recruiting

  Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

  NCT05980949· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Completed

  Relinking Diagnosed But Untreated HCV Patients Back Into Care.

  NCT05975216· Universitair Ziekenhuis Brussel· Source

• Completed

  Strength Training in Hospitalized Patients Using the Ghostly App: a Feasibility Study

  NCT05258500· Vrije Universiteit Brussel· Source

• Completed

  Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma

  NCT05938387· Phase 1· CureVac· Source

• Completed

  Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod in Pediatric Participants with Moderately to Severely Active Crohn's Disease with an Inadequate Response to Conventional Therapy

  2023-508777-91-00· Phase 2/3· Celgene International II S.a.r.l.· Source

• Completed

  A study to see how well CVGBM vaccine works at different doses and how safe it is in patients who had surgery for glioblastoma or astrocytoma

  2022-501423-25-00· Phase 1/2· Curevac AG· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions

  NCT05499832· Phase 3· Insel Gruppe AG, University Hospital Bern· Source

• Terminated

  The Safety and Feasibility of Costal Bone Marrow Aspiration During Thoracic Surgery

  NCT05251805· Universitair Ziekenhuis Brussel· Source

• Completed

  A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

  NCT05775289· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

  2023-505211-21-00· Phase 2· F. Hoffmann-La Roche AG· Source

• Completed

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· Phase 3· Amgen· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA.

  2023-504832-16-00· Phase 2· Genmab A/S· Source

• Terminated

  A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients

  NCT06025110· Phase 2· ITB-Med LLC· Source

• Completed

  CogMS - A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis

  NCT05671055· icometrix· Source

• Completed

  Different Doses of Naronapride vs. Placebo in Gastroparesis

  NCT05621811· Phase 2· Dr. Falk Pharma GmbH· Source

• Completed

  A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05595642· Phase 3· Hoffmann-La Roche· Source

Showing 50 of 117.

Conditions

Diseases this institution publishes on or runs trials for.

• Atrial fibrillation73 works · 17 trials
• Ventricular tachycardia16 works · 0 trials